BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+27.7%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$18.4B
AUM Growth
+$18.4B
(+10%)
Cap. Flow
-$969M
Cap. Flow
% of AUM
-5.27%
Top 10 Holdings %
Top 10 Hldgs %
90.4%
Holding
120
New
7
Increased
23
Reduced
7
Closed
13
Top Buys
| 1 |
Revolution Medicines
RVMD
|
$53.5M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$31.5M |
| 3 |
Roivant Sciences
ROIV
|
$30M |
| 4 |
FibroGen
FGEN
|
$23.6M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$15M |
Top Sells
Sector Composition
| 1 | Healthcare | 99.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Immatics
IMTX
$676M
| $35.8M | 0.19% |
5,187,081
| – | – |
|
|
27
Roivant Sciences
ROIV
$8.52B
| $35.3M | 0.19% |
4,777,430
+4,060,777
| +567% | +$30M |
|
28
Nurix Therapeutics
NRIX
$719M
| $34.5M | 0.19% |
3,882,125
| – | – |
|
|
KDNY
29
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $33.7M | 0.18% |
1,455,202
-1,078,900
| -43% | -$25M |
|
30
Kiniksa Pharmaceuticals
KNSA
$2.61B
| $30.1M | 0.16% |
2,799,577
| – | – |
|
|
DICE
31
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $29.7M | 0.16% |
1,035,786
+173,579
| +20% | +$4.97M |
|
32
Xenon Pharmaceuticals
XENE
$3.04B
| $26.9M | 0.15% |
751,639
| – | – |
|
|
TSVT
33
DELISTED
2seventy bio
TSVT
| $25.5M | 0.14% |
2,497,526
+434,782
| +21% | +$4.43M |
|
34
Denali Therapeutics
DNLI
$2.31B
| $25.1M | 0.14% |
1,088,738
| – | – |
|
|
DBVT
35
DBV Technologies
DBVT
$250M
| $24.7M | 0.13% |
14,614,264
| – | – |
|
36
Krystal Biotech
KRYS
$4.36B
| $24.2M | 0.13% |
302,716
| – | – |
|
|
VERV
37
DELISTED
Verve Therapeutics
VERV
| $20.4M | 0.11% |
1,416,530
| – | – |
|
38
Ultragenyx Pharmaceutical
RARE
$3.08B
| $18.9M | 0.1% |
470,974
| – | – |
|
|
BCYC
39
Bicycle Therapeutics
BCYC
$500M
| $17.9M | 0.1% |
843,814
| – | – |
|
40
Stoke Therapeutics
STOK
$1.11B
| $17.6M | 0.1% |
2,115,416
+1,006,503
| +91% | +$8.38M |
|
41
AnaptysBio
ANAB
$594M
| $16.9M | 0.09% |
775,924
| – | – |
|
42
Avidity Biosciences
RNA
$6B
| $15.4M | 0.08% |
1,004,051
+569,269
| +131% | +$8.74M |
|
|
BPMC
43
DELISTED
Blueprint Medicines
BPMC
| $15M | 0.08% |
+333,665
| New | +$15M |
|
44
ARS Pharmaceuticals
SPRY
$1.09B
| $13.1M | 0.07% |
2,006,451
| – | – |
|
45
Pacific Biosciences
PACB
$396M
| $13.1M | 0.07% |
1,127,782
| – | – |
|
46
Prime Medicine
PRME
$588M
| $12.7M | 0.07% |
1,028,466
| – | – |
|
47
Heron Therapeutics
HRTX
$210M
| $12.3M | 0.07% |
8,131,678
| – | – |
|
|
NVTA
48
DELISTED
Invitae Corporation
NVTA
| $12M | 0.07% |
8,881,104
+479,069
| +6% | +$647K |
|
49
IDEAYA Biosciences
IDYA
$2.27B
| $11.4M | 0.06% |
832,769
-835,586
| -50% | -$11.5M |
|
50
Cabaletta Bio
CABA
$138M
| $11.1M | 0.06% |
1,344,000
| – | – |
|